Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for MPDL3280A

1 Open Trial

    Trial Type Protocol No. &
    Open Date
    Summary

    Treatment

    VICCTHO1519

    10/07/2015

    A Phase III, Open-Label, Randomized Study of Atezolizumab (Anti−PDL1 Antibody) Compared with A Platinum Agent (Cisplatin or Carboplatin) in Combination with Either Pemetrexed or Gemcitabine For PD L1-Selected Chemotherapy-Naive Patients with Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer


    Print this page for your doctor